Bone marrow-derived mesenchymal stem cells protectagainst cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis

International Journal of Molecular Medicine

Volumn 32, Issue 6, 2013, Pages 1262-1272

  Qi, Shaohua ^a   Wu, Dongcheng ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Acute kidney injury; Cisplatin; Mesenchymal stem cells

Indexed keywords

CASPASE 3; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MESENCHYMAL STEM CELL; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; STEM CELL RESEARCH; WESTERN BLOTTING;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; CISPLATIN; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION; IMMUNOPHENOTYPING; KIDNEY FUNCTION TESTS; KIDNEY TUBULES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REGENERATION;

EID: 84892178356     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1517     Document Type: Article

References (56)

1. Bagshaw SM: Short- and long-term survival after acute kidney injury. Nephrol Dial Transplant 23: 2126-2128, 2008.
2. Chertow GM, Burdick E, Honour M, Bonventre JV and Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005.
3. Tögel FE and Westenfelder C: Kidney protection and regeneration following acute injury: progress through stem cell therapy. Am J Kidney Dis 60: 1012-1022, 2012.
4. Waikar SS, Liu KD and Chertow GM: Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 3: 844-861, 2008.
5. Chen YT, Sun CK, Lin YC, et al: Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 9: 51, 2011.
6. Lange C, Togel F, Ittrich H, et al: Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 68: 1613-1617, 2005.
7. Tögel F, Hu Z, Weiss K, Isaac J, Lange C and Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289: F31-F42, 2005.
8. Morigi M, Imberti B, Zoja C, et al: Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 15: 1794-1804, 2004.
9. Morigi M, Introna M, Imberti B, et al: Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26: 2075-2082, 2008.
10. Morigi M, Rota C, Montemurro T, et al: Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 28: 513-522, 2010.
11. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM and Camussi G: Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 14: 1035-1041, 2004.
12. Herrera MB, Bussolati B, Bruno S, et al: Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72: 430-441, 2007.
13. Lazzeri E, Crescioli C, Ronconi E, et al: Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. J Am Soc Nephrol 18: 3128-3138, 2007.
14. Rota C, Imberti B, Pozzobon M, et al: Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev 21: 1911-1923, 2012.
15. Li L, Black R, Ma Z, Yang Q, Wang A and Lin F: Use of mouse hematopoietic stem and progenitor cells to treat acute kidney injury. Am J Physiol Renal Physiol 302: F9-F19, 2011.
16. Horwitz EM, Le Blanc K, Dominici M, et al: Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy 7: 393-395, 2005.
17. Jia X, Xie X, Feng G, et al: Bone marrow-derived cells can acquire renal stem cells properties and ameliorate ischemia-reperfusion induced acute renal injury. BMC Nephrology 13: 105, 2012.
18. Yadav N, Rao S, Bhowmik DM and Mukhopadhyay A: Bone marrow cells contribute to tubular epithelium regeneration following acute kidney injury induced by mercuric chloride. Indian J Med Res 136: 211-220, 2012.
19. Bonegio R and Lieberthal W: Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 11: 301-308, 2002.
20. Havasi A and Borkan SC: Apoptosis and acute kidney injury. Kidney Int 80: 29-40, 2011.
21. Yuan L, Wu MJ, Sun HY, et al: VEGF-modified human embryonic mesenchymal stem cell implantation enhances protection against cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 300: F207-F218, 2011.
22. Jo SK, Cho WY, Sung SA, Kim HK and Won NH: MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 67: 458-466, 2005.
23. Ramesh G and Reeves WB: p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289: F166-F174, 2005.
24. Jiang M, Wei Q, Wang J, et al: Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056-4066, 2006.
25. Wan JX, Zou ZH, You DY, Cui J and Pan YB: Bone marrow-derived mesenchymal stem cells differentiation into tubular epithelial-like cells in vitro. Cell Biochem Funct 30: 129-138, 2012.
26. Bi B, Schmitt R, Israilova M, Nishio H and Cantley LG: Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 18: 2486-2496, 2007.
27. Haynesworth SE, Baber MA and Caplan AI: Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 166: 585-592, 1996.
28. +). Exp Hematol 26: 885-894, 1998.
29. Kim JH, Park DJ, Yun JC, et al: Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats. Am J Physiol Renal Physiol 302: F1141-F1150, 2012.
30. Zarjou A, Kim J, Traylor AM, et al: Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Renal Physiol 300: F254-F262, 2011.
31. Yasuda H, Kato A, Miyaji T, Zhou H, Togawa A and Hishida A: Insulin-like growth factor-I increases p21 expression and attenuates cisplatin-induced acute renal injury in rats. Clin Exp Nephrol 8: 27-35, 2004.
32. Nemmar A, Al-Salam S, Zia S, Yasin J, Al Husseni I and Ali BH: Diesel exhaust particles in the lung aggravate experimental acute renal failure. Toxicol Sci 113: 267-277, 2010.
33. Du H, Yao W, Fang M and Wu D: ARF triggers cell G1 arrest by a P53 independent ERK pathway. Mol Cell Biochem 357: 415-422, 2011.
34. Tsuruya K, Yotsueda H, Ikeda H, et al: Involvement of p53-transactivated Puma in cisplatin-induced renal tubular cell death. Life Sci 83: 550-556, 2008.
35. Dominici M, Le Blanc K, Mueller I, et al: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8: 315-317, 2006.
36. Sheikh-Hamad D, Cacini W, Buckley AR, et al: Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Arch Toxicol 78: 147-155, 2004.
37. Dill T, Schachinger V, Rolf A, et al: Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 157: 541-547, 2009.
38. Drexler H, Meyer GP and Wollert KC: Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial. Nat Clin Pract Cardiovasc Med 3 (Suppl 1): S65-S68, 2006.
39. Deng YB, Liu XG, Liu ZG, Liu XL, Liu Y and Zhou GQ: Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys. Cytotherapy 8: 210-214, 2006.
40. Li Y, Chen J, Zhang CL, et al: Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia 49: 407-417, 2005.
41. Ezquer F, Ezquer M, Simon V, et al: Endovenous administration of bone marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant 15: 1354-1365, 2009.
42. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ and Conget PA: Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 14: 631-640, 2008.
43. Lieberthal W, Triaca V and Levine J: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270: F700-F708, 1996.
44. Ramesh G and Reeves WB: TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285: F610-F618, 2003.
45. Liu H and Baliga R: Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 63: 1687-1696, 2003.
46. Hamar P, Song E, Kokeny G, Chen A, Ouyang N and Lieberman J: Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 101: 14883-14888, 2004.
47. Price PM, Safirstein RL and Megyesi J: Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol 286: F378-F384, 2004.
48. Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML and Santos AC: Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61: 145-155, 2008.
49. Owens DM and Keyse SM: Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213, 2007.
50. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290, 2007.
51. Rodriguez-Garcia ME, Quiroga AG, Castro J, Ortiz A, Aller P and Mata F: Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. Toxicol Sci 111: 413-423, 2009.
52. Sohn SI, Rim HK, Kim YH, et al: The ameliorative effect of 23-hydroxytormentic acid isolated from Rubus coreanus on cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull 34: 1508-1513, 2011.
53. Wei Q, Dong G, Franklin J and Dong Z: The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72: 53-62, 2007.
54. Yokoo T, Ohashi T, Shen JS, et al: Human mesenchymal stem cells in rodent whole-embryo culture are reprogrammed to contribute to kidney tissues. Proc Natl Acad Sci USA 102: 3296-3300, 2005.
55. Duffield JS and Bonventre JV: Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int 68: 1956-1961, 2005.
56. Duffield JS, Park KM, Hsiao LL, et al: Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest 115: 1743-1755, 2005.